Welcome to our dedicated page for Talphera news (Ticker: tlph), a resource for investors and traders seeking the latest updates and insights on Talphera stock.
Talphera Inc. (TLPH) is a specialty pharmaceutical innovator developing therapies for critical care environments, with a focus on nafamostat-based anticoagulants and pre-filled syringe technologies. This page aggregates all official announcements, clinical trial milestones, and regulatory developments related to the company's pursuit of safer treatment protocols in high-risk medical settings.
Investors and healthcare professionals will find timely updates on key initiatives including the NEPHRO study evaluating Niyad™ for extracorporeal circuits, progress toward Breakthrough Device designation, and strategic partnerships advancing pre-filled syringe candidates. The curated newsfeed serves as a comprehensive resource for tracking pipeline advancements and evidence-based therapeutic innovations.
Content spans quarterly financial results, FDA correspondence, peer-reviewed research publications, and manufacturing updates. All materials are sourced directly from company disclosures to ensure compliance with financial reporting standards.
Bookmark this page for structured access to Talphera's evolving clinical strategy and pharmaceutical development progress. Cross-reference announcements with SEC filings via provided documentation links for complete context.
Talphera (Nasdaq: TLPH) has announced the enrollment of the first patient in its NEPHRO CRRT registrational trial, evaluating nafamostat for anticoagulation in extracorporeal circuits. The study will involve 166 patients across 14 clinical sites in the United States. The primary endpoint is the mean post-filter activated clotting time over the first 24 hours, comparing nafamostat to placebo.
Dr. Stuart Goldstein, a renowned nephrologist, enrolled the first patient. Nafamostat has been a standard of care in Japan and South Korea for over 30 years, and Talphera aims to make it available in the U.S. market if approved. The company views this as a significant milestone in addressing the limitations of current anticoagulation options for continuous renal replacement therapy (CRRT).
Talphera (Nasdaq: TLPH) announced its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Initiation of patient screening at multiple clinical sites for the NEPHRO CRRT registrational study, which will assess nafamostat's safety and effectiveness in 166 patients across up to 14 clinical sites.
2. Cash and investments of $14.0 million as of June 30, 2024.
3. Q2 2024 financial results: Combined R&D and SG&A expenses of $4.3 million, net loss from continuing operations of $3.8 million, and net loss attributable to common shareholders of $3.8 million ($0.15 per share).
4. Appointment of Dr. Shakil Aslam as Chief Development Officer, who will succeed Dr. Palmer as Chief Medical Officer upon her retirement in October.
Talphera Inc. (Nasdaq: TLPH), a specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results after market close on Wednesday, August 14, 2024. The company will host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide a business update.
Investors can access the webcast through the company's website or join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using the conference ID 28132. The webcast will include a slide presentation, and a replay will be available on Talphera's website for 90 days following the event.
Talphera, a specialty pharmaceutical company, has announced the grant of inducement awards to Dr. Shakil Aslam, the newly appointed Chief Development Officer. These awards, approved by Talphera's Board of Directors on May 20, 2024, include a non-statutory stock option for 185,000 shares and a restricted stock unit award for 32,000 shares. The stock options have an exercise price of $1.08 per share and will vest 25% on May 20, 2025, with the remaining shares vesting monthly over three years. The restricted stock units will vest in equal installments over three years, starting May 20, 2025. These awards were granted under Nasdaq Listing Rule 5635(c)(4) but are governed by Talphera's 2020 Equity Incentive Plan.
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the A.G.P. Virtual Healthcare Conference on May 21, 2024, at 10:40 a.m. ET. The management will engage in a fireside chat format to discuss the company's innovative therapies developed for medically supervised settings. This session aims to provide insights into Talphera's business strategies and future plans. Attendees can join the webcast through a provided link.
Talphera (Nasdaq: TLPH) announced its Q1 2024 financial results and provided a corporate update. The company reported cash and investments of $18.6 million as of March 31, 2024. Combined R&D and SG&A expenses were $4.2 million, down from $5.3 million in Q1 2023, due to reduced headcount from divesting DSUVIA. Net loss from continuing operations was $4.0 million, compared to net income of $0.1 million in Q1 2023, due to changes in the fair value of the company's warrant liability. The NEPHRO CRRT study is set to enroll its first patients in Q2 2024. Dr. Shakil Aslam joins as Chief Development Officer on May 20, 2024.
Talphera, Inc. (NASDAQ: TLPH) will release its first quarter 2024 financial results on May 14, 2024, followed by a live webcast and conference call to discuss the results and provide a business update. The webcast can be accessed on the company's website, and the conference call details are provided for investors.
FAQ
What is the current stock price of Talphera (tlph)?
What is the market cap of Talphera (tlph)?
